A separate study examining the development of resistance in EGFR-mutant non-small-cell lung cancers (NSCLCs) to EGFR inhibitors revealed that resistance emerged through the transformation of NSCLC to small-cell lung cancer (SCLC). Here, EGFR is linked to non-small cell lung carcinoma.